GSK plc GSK
NYSE
$46.27-0.65 (-1.39%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
GSK PLC (LSE:GSK, NYSE:GSK) is expected to deliver a broadly in-line third quarter as weaker vaccine sales are offset by strength in HIV treatments and respiratory drug Nucala, according to RBC Capital Markets. The broker reiterated its Sector Perform rating and 1,975p price target ahead of...
GSK (LSE:GSK) announced a new collaboration with Chai Discovery to apply AI-driven protein design in its drug discovery pipeline. The partnership gives GSK access to Chai Discovery's protein folding and design models that are focused on early stage R&D. Internal GSK evaluations reported hits against all tested targets when using Chai Discovery's AI tools in preclinical research. The Chai Discovery AI protein design collaboration is important, but investors should weigh it alongside GSK's...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.
GSK is in the latest 13F portfolio of 1 of the gurus we follow.
